TD Cowen analyst Tara Bancroft has maintained their bullish stance on TCRX stock, giving a Buy rating on November 8.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tara Bancroft’s rating is based on the promising data from TScan Therapeutics’ Phase I ALLOHA trial, which showed a significant reduction in relapse rates for TSC-101 in heme malignancies compared to the control group. The observed 18% relapse rate in the TSC-101 arm is notably lower than the control’s 36%, indicating improved relapse-free survival and overall survival metrics. These results are expected to de-risk the upcoming pivotal trial, which is set to begin following feedback from the FDA and an updated trial design.
Tara Bancroft also notes that the updated trial design, which now includes an internal control, should streamline the trial process and address operational challenges. By focusing on AML and MDS patients, TScan Therapeutics aims to reduce disease heterogeneity, which could enhance the trial’s efficacy and outcomes. These strategic adjustments, coupled with the strong preliminary data, underpin the Buy rating for TScan Therapeutics’ stock.
According to TipRanks, Bancroft is a 4-star analyst with an average return of 16.6% and a 48.45% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Geron, and Telix Pharmaceuticals.
In another report released on November 8, LifeSci Capital also maintained a Buy rating on the stock with a $6.00 price target.